<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049114</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02500</org_study_id>
    <secondary_id>02-05-125</secondary_id>
    <secondary_id>AECM-0205125</secondary_id>
    <secondary_id>NCI-5598</secondary_id>
    <secondary_id>CDR0000257811</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <nct_id>NCT00049114</nct_id>
  </id_info>
  <brief_title>Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Tipifarnib may stop the growth&#xD;
      of tumor cells by blocking the enzymes necessary for their growth. Combining tipifarnib with&#xD;
      doxorubicin and cyclophosphamide may kill more tumor cells. Phase II trial to study the&#xD;
      effectiveness of combining tipifarnib with doxorubicin and cyclophosphamide in treating women&#xD;
      who have locally advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of tipifarnib when administered with doxorubicin and&#xD;
      cyclophosphamide in women with metastatic breast cancer (non-regional stage IV disease).&#xD;
      (Phase I closed to accrual as of 1/19/04) II. Determine the pathologic complete remission&#xD;
      rate in patients with locally advanced breast cancer (stages IIB, IIIA, IIIB, or IIIC)&#xD;
      treated with the recommended phase II dose of this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical complete response rate in patients treated with this regimen.&#xD;
&#xD;
      II. Determine the toxicity profile of this regimen in these patients. III. Correlate&#xD;
      pretreatment levels of ErbB1, 2, 3, 4 and phosphorylated levels of Akt, STAT3, and Erk ½ with&#xD;
      clinical response in these patients and with percent inhibition of proliferation (Ki-67) and&#xD;
      percent induction of apoptosis in post-treatment tumor specimens.&#xD;
&#xD;
      IV. Correlate percent decrease of farnesyltransferase (FTase) activity levels, HDJ-2&#xD;
      farnesylation, phospho-Akt, phospho-STAT3, and phospho-Erk ½ with clinical response rates in&#xD;
      these patients and with percent inhibition of proliferation (Ki-67) and percent inhibition of&#xD;
      apoptosis.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of tipifarnib. Patients are stratified&#xD;
      according to presence of inflammatory carcinoma (yes vs no).&#xD;
&#xD;
      PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive&#xD;
      doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral&#xD;
      tipifarnib twice daily on days 2-7, and filgrastim (G-CSF) subcutaneously on days 2-13.&#xD;
      Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and&#xD;
      doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of&#xD;
      1/19/04). After the fourth course, patients may undergo complete resection.&#xD;
&#xD;
      Patients are followed every 3-4 months for 3 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-12 patients will be accrued for phase I (closed to accrual&#xD;
      as of 1/19/04) of this study. A total of 21-50 patients will be accrued for phase II of this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response in the breast</measure>
    <time_frame>8 weeks</time_frame>
    <description>95% confidence intervals of these estimates will be obtained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have a clinical complete response</measure>
    <time_frame>8 weeks</time_frame>
    <description>95% confidence intervals of these estimates will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 toxicities assessed using NCI CTCAE version 3.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Toxicity will be summarized by type, frequency and severity. This will be compared with an historical database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median disease-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be summarized, and 95% confidence intervals of these estimates will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients free of disease</measure>
    <time_frame>1 year</time_frame>
    <description>Will be summarized, and 95% confidence intervals of these estimates will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients free of disease</measure>
    <time_frame>2 years</time_frame>
    <description>Will be summarized, and 95% confidence intervals of these estimates will be obtained.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Inflammatory Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo complete resection</description>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
          -  Phase I (closed to accrual as of 1/19/04):&#xD;
&#xD;
               -  Nonregional stage IV disease&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  Locally advanced disease, according to AJCC staging criteria:&#xD;
&#xD;
                    -  Stage IIB&#xD;
&#xD;
                    -  Stage IIIA&#xD;
&#xD;
                    -  Stage IIIB&#xD;
&#xD;
                    -  Stage IIIC&#xD;
&#xD;
          -  At least 1 bidimensionally or unidimensionally measurable indicator lesion&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  LVEF normal&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No other invasive malignancies within the past 5 years except curatively treated basal&#xD;
             cell or squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to tipifarnib or other agents used in the study (e.g., imidazoles or&#xD;
             quinolones)&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  Phase I (closed to accrual as of 1/19/04):&#xD;
&#xD;
               -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or&#xD;
                  mitomycin) and recovered&#xD;
&#xD;
               -  No more than 1 prior adjuvant/neoadjuvant regimen and 1 prior regimen for&#xD;
                  metastatic disease&#xD;
&#xD;
               -  Prior doxorubicin allowed provided the following are true:&#xD;
&#xD;
                    -  Used in adjuvant setting&#xD;
&#xD;
                    -  Cumulative dose was no greater than 240 mg/m^2&#xD;
&#xD;
                    -  At least 1 year between completion of adjuvant therapy and relapse&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  No prior chemotherapy for locally advanced breast cancer&#xD;
&#xD;
          -  At least 1 week since prior tamoxifen or other selective estrogen receptor modulators&#xD;
             for prevention or other indications (e.g., osteoporosis, ductal carcinoma in situ, or&#xD;
             invasive breast cancer)&#xD;
&#xD;
          -  Phase I (closed to accrual as of 1/19/04):&#xD;
&#xD;
               -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  No prior radiotherapy for locally advanced breast cancer&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  No antacids within 2 hours of study drug administration&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Sparano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

